PD ExpertBriefing: Impulsive and Compulsive Behaviors in Parkinson s Disease

Similar documents
Parkinson s Disease: The Quintessential Neuropsychiatric Illness

Parkinson s Disease Duncan Gerry. 5/12/12 All drugs are poison

Prevalence of hypersexual behavior in Parkinson s disease patients: Not restricted to males and dopamine agonist use

Behavioral Aspects of Parkinson s Disease

Psychiatric aspects of Parkinson s disease an update

NIH Public Access Author Manuscript Arch Neurol. Author manuscript; available in PMC 2006 December 30.

A survey of impulse control disorders in Parkinson s disease patients in Shanghai area and literature review

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Best Medical Treatments for Parkinson s disease

Restless Leg Syndrome What does it mean to you in the middle of the night?

Depression & Anxiety. What can I do? What are other possible treatments? What is this? Why does this happen? KEY POINTS

Non-Motor Symptoms of Parkinson s Disease

Elements for a public summary

Impulse control behaviours in a Malaysian Parkinson s disease population

Communicating About OFF Episodes With Your Doctor

PD ExpertBriefing: What s in the Parkinson s Pipeline

Impulse Control Disorders in PD

Medical Treatment of Problem Gambling. Donald W. Black, M.D. Roy J. and Lucille A. Carver College of Medicine Department of Psychiatry

Client Information Form

Real Men Real Depression

Understanding and Treating Behavioral Addictions

The Fresco Institute for Parkinson's and Movement Disorders

Continuous dopaminergic stimulation

Managing Challenging Behaviors

Dr Barry Snow. Neurologist Auckland District Health Board

Design Process for Potential Change-Energy Healing the Heart

Weaning off requip. Cari untuk: Cari Cari

ADHD & Addictions -What We Know

Impulse control disorders in Parkinson s disease: clinical characteristics and implications

ObsessiveCompulsive. Disorder: When Unwanted Thoughts Take Over. Do you feel the need to check and. re-check things over and over?

Addiction Overview. Diane A. Rothon MD. Causes Consequences Treatments. Methadone/Buprenorphine 101 April 1, 2017

PPMI Cognitive-Behavioral Working Group. Daniel Weintraub, MD

Swiss Summary of the Risk Management Plan (RMP) for Ongentys (opicapone) 50 mg hard capsules

Treatment of Parkinson s Disease: Present and Future

Appendix N: Research recommendations

Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations

6B / Boswell, Grant and Slutske Day 2 August 14, 2008

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Annex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Managing Challenging Behaviors

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Impulse Control Disorders in Parkinson s Disease in a South Indian cohort

MADOPAR 100 mg/25 mg Tablets

Summary of Patient < 3y at Visit 11 (90 months)

DYSKINESIA SYMPTOM TRACKER

PUBLIC SUMMARY OFRISK MANAGEMENT PLAN

ReQuip 0.25 mg, 1 mg, 2 mg, 5 mg film-coated tablets ropinirole (as the hydrochloride)

MIRAPEXIN 0.088mg tablets; 0.18mg tablets; 0.35mg tablets; 0.7mg tablets; 1.1mg tablets

Client s Name: Today s Date: Partner s Name (if being seen as a couple): Address, City, State, Zip: Home phone: Work phone: Cell phone:

Nebraska Bariatric Medicine 8207 Northwoods Dr., Suite 101 Lincoln, NE MEDICAL HISTORY

Basics of Restless Legs Syndrome (Willis-Ekbom Disease)

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Thompson Centre Intensive Treatment Program Physician Referral Form

An Overview of Gambling Disorder. Timothy Fong MD UCLA Gambling Studies Program IDAA Annual Meeting August 2018

Optimizing Clinical Communication in Parkinson s Disease:

Quick Start Guide for Video Chapter 2: What Is Addiction?

BASIC VOLUME. Elements of Drug Dependence Treatment

Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care

ropinirole Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

FAMILY AND ADOLESCENT MENTAL HEALTH: THE PEDIATRICIAN S ROLE

HDSA welcomes you to Caregiver s Corner. Funded by an educational grant from

Compulsive Shopper or Not? Meg Hinton, Psychologist Hinton, Bernier Consulting December 5, 2009

Depression. Northumberland, Tyne and Wear NHS Trust (Revised Jan 2002) An Information Leaflet

PD ExpertBriefing: Fatigue, Sleep Disorders and Parkinson's Disease. Presented By:

ADULT QUESTIONNAIRE. Date of Birth: Briefly describe the history and development of this issue from onset to present.

Restless Legs Syndrome (RLS) is a common yet

Huntington s & Parkinson s Diseases: Neurologic & Psychiatric Issues. Huntington s Disease

Gambling und Gaming:

Pediatric Psychopharmacology

The prevalence and clinical characteristics of pathological gambling in Parkinson s disease: an evidence-based review

Depression Fact Sheet

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016

Risk Management Plan Rasagiline tablets

What is the DSM. Diagnostic and Statistical Manual of Mental Disorders Purpose

ReQuip XL (logo) 2 mg, 4 mg, 8 mg, prolonged-release tablets ropinirole (as hydrochloride)

TO BE MOTIVATED IS TO HAVE AN INCREASE IN DOPAMINE. The statement to be motivated is to have an increase in dopamine implies that an increase in

Parkinson s Founda.on

HD 101: Cognition and HD. Daniel O. Claassen, MD MS Assistant Professor of Neurology Director: HD and Chorea Clinic Vanderbilt University

Evidence-Based Treatment Approaches for Gambling Disorder

Henrike B. Kroemer, Ph.D. ADULT HISTORY FORM

10th Medicine Review Course st July Prakash Kumar

CBT Intake Form. Patient Name: Preferred Name: Last. First. Best contact phone number: address: Address:

Package leaflet: Information for the user

Package leaflet: Information for the patient. Pramipexol Teva Pharma 2.62 mg prolonged-release tablets

Huntington s & Parkinson s Diseases: Neurologic & Psychiatric Issues. Burton Scott PhD, MD Duke Movement Disorders Center Durham, NC

Any interventions, where RCTs in PD are not available, are not included in the tables.

World Journal of Pharmaceutical and Life Sciences WJPLS

Psychiatric and Behavioral Challenges in HD

ORIGINAL CONTRIBUTION. Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease

Integrated Care Model for Problem Gambling

Chapter 7. Screening and Assessment

Opiate Use Disorder and Opiate Overdose

Managing Mental Health (at Work)

Alison Charleston 1 st September 2016

Restore Counseling Center 630 E Southlake Blvd, Ste 127, Southlake, Tx

Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic

EATING DISORDERS AND SUBSTANCE ABUSE. Margot L. Waitz, DO October 7, 2017 AOAAM - OMED

Chapter 7. Screening and Assessment

PERSONAL HISTORY QUESTIONNAIRE

Jonathan Haverkampf BIPOLAR DISORDR BIPOLAR DISORDER. Dr. Jonathan Haverkampf, M.D.

Transcription:

PD ExpertBriefing: Impulsive and Compulsive Behaviors in Parkinson s Disease Presented By: Daniel Weintraub, M.D. Associate Professor of Psychiatry, University of Pennsylvania; Parkinson s Disease and Mental Illness Research, Education and Clinical Centers, Philadelphia VA Medical Center Tuesday, September 27, 2011 at 1:00 PM EDT

Welcoming Remarks Robin Elliott Executive Director Parkinson s Disease Foundation

Goals Provide overview of impulsive and compulsive behaviors in PD: Presentation Epidemiology Potential risk factors Assessment Management

Presentation

Vignettes - Gambling My father has been treated for Parkinson s since his diagnosis in his late 40 s, over 25 yrs ago. He has developed a severe compulsive gambling problem over the years such that he is now destitute and broke. He owned multiple successful automobile dealerships and has been on the board of the bank for many years His disease has required increasing amounts of multiple meds, including dopaminergic drugs The following year he (the neurologist) said it was a known effect but knew of no treatment I am concerned about suicide I am wondering from all I have read this week if there is a compulsion drug he can be treated with for this Some recommend weaning off the dopaminergic drugs. I am not sure how this would go for him.

Vignettes Eating and Sex During the day I can control my appetite and I have will power. Then in the evening right before bed time it starts and I feel the urge to eat. I have gained 15 lbs and I have been thin all my life so this is a shock for me. Now I am on a diet, it s slow because I keep wanting to eat When I wake up in the morning I see the number of wrappers that are at the bed side and it is a shock. It is like an urge that you just cannot satisfy. It happens at night when I am alone. I often go on the internet and look at websites that are sexual in nature. It causes me to lose a lot of sleep. The lack of sleep is causing problems at work; some people are starting to notice that I am exhausted in the afternoon I am not as productive as I was before I have let a lot of things (around the house) go because I spend my time fantasizing and on the internet.

Issues Highlighted by Cases Association with PD medications Behaviors atypical or excessive for individual Lack of control over behaviors Lack of pleasure associated with behaviors Needing vs. wanting Significant distress or impairment in many cases, often enduring Difficult clinical management decisions

Terminology Impulse control disorders (ICDs) are category of psychiatric disorders in DSM-IV Essential feature failure to resist impulse, drive, or temptation to perform act that is harmful to person or others ICDs accepted as term for major disorders reported to occur in PD Gambling Buying Sexual behaviors Eating

Presentation Gambling Can involve frequent low stakes (slots, scratch cards), casinos Sexual behavior Demands on spouse, internet, prostitution, changes in sexual orientation Buying Purchasing same items repeatedly Eating Cravings for certain foods (sweets), overnight eating

Related Disorders Dopamine dysregulation syndrome (DDS) More like addiction Misuse and escalating dose of medication Occurs with levodopa or subcutaneous apomorphine typically Appears less common in US than in Europe Punding (fascination with meaningless objects or activities) Hobbyism (more complex task preoccupation) Walkabout Other (hoarding, reckless driving)

Beneficial Changes in Behaviors? Increased sexual drive in patients with decreased sexual drive and performance? Increased appetite in patients that lose weight? Enhance creativity? Increased motivation in patients with apathy or avoidance? Increased enjoyment? These possibilities have not been adequately explored in Parkinson s disease.

Epidemiology

ICDs in Untreated PD Antonini et al. Movement Disorders 2011;26:464-468.

DOMINION Study Study of frequency and correlates of 4 ICDs in PD MAGS for gambling, MIDI for buying and sexual behavior, and DSM-IV criteria for binge-eating 46 PD centers in US and Canada 3090 patients 75 years old completed assessments 66% of patients were taking a dopamine agonist (DA) Overall, 86.8% of patients were taking levodopa Weintraub et al. Archives of Neurology 2010;67:589-595.

Frequency of ICDs At least one ICD identified in 14% of patients 29% of ICD patients had 2 ICDs Frequencies of individual ICDs were: Problem/pathological gambling = 5.0% Compulsive sexual behavior = 3.5% Compulsive buying = 5.7% Binge-eating disorder = 4.3%

Potential Risk Factors

Relationship to Dopamine Agonist Treatment ICD type DA treatment status Current ICD N (%) No current ICD N (%) Any ICD No dopamine agonist 72 (6.9) 978 (93.1) <.001 P value (CMH-test); odds ratio [95% CI] Dopamine agonist 348 (17.1) 1692 (82.9) 2.72 [2.08;3.54] Problem/pathological No dopamine agonist 24 (2.3) 1026 (97.7) <.001 gambling Dopamine agonist 130 (6.4) 1910 (93.6) 2.82 [1.81;4.39] Pathological gambling No dopamine agonist 17 (1.6) 1033 (98.4).004 only Dopamine agonist 72 (3.5) 1968 (96.5) 2.15 [1.26;3.66] Compulsive sexual No dopamine agonist 18 (1.7) 1032 (98.3) <.001 behaviour Dopamine agonist 90 (4.4) 1950 (95.6) 2.59 [1.55;4.33] Compulsive buying No dopamine agonist 30 (2.9) 1020 (97.1) <.001 Dopamine agonist 147 (7.2) 1893 (92.8) 2.53 [1.69;3.78] Binge-eating disorder No dopamine agonist 18 (1.7) 1032 (98.3) <.001 Dopamine agonist 114 (5.6) 1926 (94.4) 3.34 [2.01;5.53]

Specific Dopamine Agonists ICD type Specific DA Current ICD N (%) No current ICD N (%) Any ICD Ropinirole 101 (15.5) 550 (84.5).14 P value (CMH-test); odds ratio [95% CI] Pramipexole 228 (17.7) 1058 (82.3) 1.22 [0.94;1.57] Problem/pathological Ropinirole 37 (5.7) 614 (94.3).44 gambling Pramipexole 83 (6.5) 1203 (93.5) 1.17 [0.78;1.76] Pathological gambling Ropinirole 24 (3.7) 627 (96.3).69 only Pramipexole 42 (3.3) 1244 (96.7) 0.90 [0.54;1.51] Compulsive sexual Ropinirole 28 (4.3) 623 (95.7).75 behaviour Pramipexole 58 (4.5) 1228 (95.5) 1.08 [0.68;1.71] Compulsive buying Ropinirole 51 (7.8) 600 (92.2).58 Pramipexole 87 (6.8) 1199 (93.2) 0.90 [0.63;1.30] Binge-eating disorder Ropinirole 28 (4.3) 623 (95.7).06 Pramipexole 80 (6.2) 1206 (93.8) 1.53 [0.98;2.39]

Other Factors Associated with ICDs Variable * Entire Study Population (N=3090) Odds ratio [95% CI] P value PAR% & Age ( 65 years vs. >65 years) 2.50 [1.98; 3.15] <0.001 41.2% Marital status (not married vs. married) 1.48 [1.16; 1.89] 0.002 7.4% Country (living in United States) 1.62 [1.25; 2.10] <0.001 27.9% Current smoking (yes vs. no) 1.70 [1.07; 2.70] 0.02 2.9% Family history gambling problems (yes vs. no) 2.08 [1.33; 3.25] 0.001 1.5% DA treatment (yes vs. no) 2.72 [2.07; 3.57] <0.001 49.3% Levodopa treatment (yes vs. no) 1.51 [1.09; 2.09] 0.01 9.6%

Dose Effects Examining patients on a DA (N=2040) No DA dosage effect There was levodopa dosage effect (P=0.008) Examining patients on levodopa only (N=991) Higher levodopa dosage was associated with current ICD (P=0.002)

Other Factors Associated with ICDs ICDs more common in US (15.0%) than Canada (9.8%) Specifically compulsive gambling and buying Even controlling for differences in medication exposure No sex differences in ICDs overall, but Sexual behaviors far more common in men Buying and binge-eating more common in women Family history of gambling problems more common in three of the four ICDs (all except sexual behaviors)

DOMINION Study - Amantadine Data Weintraub et al. Annals of Neurology 2010;68:963-968.

Assessment

Questionnaire for Impulsive-Compulsive Disorders in Parkinson s Disease (QUIP) Valid as screening instrument for ICDs and related disorders Simple and short (<5 minutes) Clinical interview needed for screen + patients Interview should focus on all ICDs and related behaviors

QUIP-Rating Scale Weintraub et al. (under review).

Patient vs. Informant Reporting of ICD Symptoms Using QUIP Papay et al. Parkinsonism and Related Disorders 2011;17:153-155.

Management

Current Management Options Do nothing Assess clinical significance Some patients unable or reluctant to make adjustments to PD pharmacotherapy Alterations to PD pharmacotherapy Changes to DA therapy with increase in levodopa to help motor symptom management Consider deep brain stimulation (DBS) Psychopharmacology Antidepressants, antipsychotics

Amantadine for Gambling in PD Symptom Assessment Scale (SAS) and Yale- Brown Obsessive- Compulsive Scale (Y- BOCS) score changes. Both scores reduced by amantadine (p < 0.001 compared to baseline). A = amantadine P = placebo Thomas et al. Annals of Neurology 2010;68:400-404.

Ongoing Clinical Trial Michael J. Fox Foundation grant Randomized, double-blind, placebo-controlled clinical trial of naltrexone for all ICDs Naltrexone is an opioid receptor anatagonist FDAapproved for the treatment of alcoholism Modulatory role for opioid peptides in the nigrostriatal dopaminergic pathway 48 subjects with 1 of 4 common ICDs Contact Information: Kim Papay kimberly.papay@uphs.upenn.edu 215-349-8390

Conclusions - Epidemiology ICDs in PD are Relatively common A range occur Often co-morbid Psychiatric co-morbidity common Associated with DA use as a class Associated with levodopa and amantadine use to lesser extent Dose effects for levodopa May have other pre-morbid risk factors

Conclusions Assessment and Management Must ask about a range of symptoms Agreement fair between patients and informed others Screening instruments and rating scales available for clinical use Range of management strategies available Need for psychopharmacological options with established efficacy and good tolerability

Acknowledgements Patients, colleagues, and research staff at PD Centers at University of Pennsylvania Philadelphia Veterans Affairs Medical Center Grant support from NIMH, NINDS, State of PA, VA, and Fox Foundation for Parkinson s Research

Questions and Answers